Are Research Peptides Legal in the United States? A Regulatory Explainer

Introduction

Research peptides are legal to manufacture, sell and buy in the United States when they are labeled, described and marketed solely for laboratory research and no claim is made about their use in humans. What makes a peptide unlawful is marketing or distribution for human use, which turns the same molecule into an unapproved new drug under the Federal Food, Drug, and Cosmetic Act. Peptides are not controlled substances as a class.

This article is general legal information about the US regulatory framework, not legal advice, and it does not comment on the affairs of any individual company. It draws only on statutes, regulations, FDA documents and the World Anti-Doping Agency (WADA) list cited in the references.

Key facts

• The Controlled Substances Act's five schedules at 21 U.S.C. 812 contain no category for peptides as a class [1].
• Anabolic steroids are Schedule III, defined at 21 U.S.C. 802(41) as substances "chemically and pharmacologically related to testosterone"; they are not peptides [1, 2].
• Human growth hormone (somatrem, somatropin or an analogue) is subject to a separate federal offense at 21 U.S.C. 333(e) for distribution outside an authorized medical use [3].
• A drug is defined by intended use at 21 U.S.C. 321(g)(1), and intent is judged from all the circumstances of marketing under 21 CFR 201.128 [4, 5].
• On September 29, 2023 the FDA placed GHRP-2, GHRP-6 and ipamorelin acetate in category 2 under its 503B interim policy, and kisspeptin-10 under 503A [11].
• The FDA issued warning letters to online peptide sellers on December 10, 2024 and August 24, 2026, each rejecting research-use-only labels on the basis of website content [13, 14].
• The FDA's Pharmacy Compounding Advisory Committee scheduled BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon related substances for review on July 23 to 24, 2026 [12].
• WADA's 2026 Prohibited List, effective January 1, 2026, prohibits section S2 peptide hormones, releasing factors and growth factors at all times [15].

Are research peptides legal in the United States?

Yes, within a defined boundary: a synthetic peptide may lawfully be made, sold and purchased as a research-use-only (RUO) laboratory material, and it becomes unlawful to sell when marketed or distributed for human use. Federal law regulates peptides through the drug definition of the Federal Food, Drug, and Cosmetic Act (FDCA), not through scheduling, so legality turns on intended use rather than the identity of the molecule [4, 5].

Three questions are often run together. Legality of sale for research asks whether a supplier may offer the material as a laboratory reagent. Legality of possession asks whether holding it is an offense, which for a non-scheduled peptide it is not under the Controlled Substances Act [1]. Legality of marketing for human use asks whether the seller has made the article a drug: 21 U.S.C. 355(a) bars unapproved new drugs from interstate commerce, and 21 U.S.C. 331(d) makes introducing one a prohibited act [6, 7].

Are peptides controlled substances?

No. Peptides are not scheduled as a class under the Controlled Substances Act, and none of the five schedules at 21 U.S.C. 812 lists a general peptide category [1].

Two federal provisions are sometimes mistaken for peptide scheduling. Anabolic steroids are Schedule III, but 21 U.S.C. 802(41)(A) defines them as "any drug or hormonal substance, chemically and pharmacologically related to testosterone"; these are cholesterol-derived lipids, not chains of amino acids [1, 2].

Separately, 21 U.S.C. 333(e) creates an offense for knowingly distributing human growth hormone, defined as somatrem, somatropin or an analogue of either, for any use other than an authorized medical use under a physician's order [3]. The provision names that protein specifically; it is not a general rule for peptides. A peptide that is neither scheduled nor human growth hormone is regulated as a potential drug under the FDCA, not as a controlled substance.

What makes a peptide a "drug" under US law?

A peptide is a drug when it is intended to be one. The FDCA defines a drug, in relevant part, as an article "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals" or "intended to affect the structure or any function of the body of man or other animals" [4]. Chemistry does not appear in the definition; intent does.

The FDA's regulation on the meaning of "intended uses," 21 CFR 201.128, states that intent is determined by "the objective intent of the persons legally responsible for the labeling of an article," which "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article," including "labeling claims, advertising matter, or oral or written statements" [5].

The consequence is that the same amino-acid sequence can be a laboratory reagent when offered without human-use claims and an unapproved drug when offered with them. Website copy, product descriptions and social media are all part of the record from which intent is inferred. The article on what research peptides are sets out the three categories (approved, compounded, research) a single sequence can occupy.

What does research use only mean legally?

Research use only is a labeling designation stating that a material is supplied solely for laboratory investigation. It is consistent with lawful sale when every circumstance of marketing matches it, and insufficient when other circumstances point to human use: an RUO label is evidence of intended use, not a shield against contrary evidence [5].

Two limits apply. The FDA's only formal RUO guidance concerns in vitro diagnostic products and does not govern peptides [20]. And in its warning letters the FDA said directly that website evidence established an intended human use despite labels reading "for research use only" and "not for human or veterinary use" [13, 14]. The August 2026 letter also cited the marketing of bacteriostatic water as a solvent for the seller's peptides as evidence of intended human use [14].

What has the FDA done about peptides sold for compounding and for human use?

The FDA has acted in two separate lanes: the compounding framework, which governs whether licensed compounders may use a substance, and enforcement against online sellers marketing peptides for human use. The table records dated actions with their FDA sources.

Date	Action	What it covered	Source
September 29, 2023	Category 2 placement, interim compounding policies	GHRP-2, GHRP-6, ipamorelin acetate (503B); kisspeptin-10 (503A)	FDA bulk-substances page [11]
December 10, 2024	Warning letter, Alabama online seller	Semaglutide, retatrutide, cagrilintide, tirzepatide, mazdutide under RUO labels; 21 U.S.C. 355(a), 331(d) cited	FDA warning letter [13]
January 7, 2025	Revision of the 503A interim policy	Substances nominated from that date are no longer placed in categories 1, 2 or 3	FDA 503A page [10]
Page current April 22, 2026	Nominations recorded as withdrawn	AOD-9604, BPC-157, CJC-1295, epitalon, GHK-Cu, melanotan II, selank, semax, thymosin alpha-1, thymosin beta-4	FDA bulk-substances page [11]
July 23 to 24, 2026	Pharmacy Compounding Advisory Committee meeting	BPC-157, KPV, TB-500, MOTS-c (July 23); emideltide, semax, epitalon (July 24), for the 503A bulks list	FDA meeting notice [12]
August 24, 2026	Warning letter, Florida online seller	Semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin, bremelanotide under RUO labels	FDA warning letter [14]

The compounding actions concern sections 503A and 503B of the FDCA, which allow licensed pharmacists, physicians and registered outsourcing facilities to prepare drugs from bulk substances under stated conditions [8, 9]. Category 2 substances are those for which the FDA "has identified significant safety risks" [10]. Category placement speaks to compounders; it neither creates nor removes any status for research materials, which sit outside the compounding framework.

The enforcement actions concern sellers. In both letters the FDA quoted product-page language describing effects in humans and concluded that the products were unapproved new drugs, notwithstanding RUO labels [13, 14]. The difference between the two lanes is set out in peptide therapy versus research peptides.

Are research peptides legal for athletes?

Under sporting rules, most research peptides of interest are prohibited for athletes bound by the World Anti-Doping Code, whatever their status under US law. WADA's 2026 Prohibited List, in effect from January 1, 2026, places peptide hormones, growth factors, related substances and mimetics in section S2, prohibited at all times [15].

Section S2.2.4 names GHRH analogues (CJC-1293, CJC-1295, sermorelin, tesamorelin), growth hormone secretagogues (including ipamorelin and ibutamoren) and GH-releasing peptides (including hexarelin, GHRP-2 and GHRP-6). Section S2.2.3 names growth hormone fragments such as AOD-9604, and section S2.3 names thymosin beta-4 and its derivatives, giving TB-500 as the example [15]. Anti-doping laboratories screen for such peptides by mass spectrometry, as Görgens, Thevis and colleagues described in 2018 [16] and as Esposito and colleagues applied to TB-500 in 2012 [17].

The WADA regime is separate from criminal law and the FDCA: it is enforced through sporting sanctions such as ineligibility, applies only to those bound by the Code, and does not itself make possession or sale a crime. A peptide can be lawful to sell for research and still be prohibited for a competing athlete.

Is it legal to buy research peptides online?

Buying a research peptide from a domestic supplier that labels and markets it solely for laboratory research is not prohibited by federal statute, and simple possession of a peptide that is neither scheduled nor human growth hormone is not an offense under the Controlled Substances Act [1, 3]. The prohibitions in 21 U.S.C. 331 are directed at the seller's conduct and the article's intended use [7].

Importation is different. The FDA states that "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use," and its personal-importation policy describes only a narrow enforcement discretion for prescription products meeting stated conditions [18].

State law varies. States maintain their own controlled-substance schedules, pharmacy-practice statutes and consumer-protection laws. This article states the federal position and does not catalog individual state rules; a question about a specific jurisdiction is one for a licensed attorney.

What distinguishes a lawful research supplier?

A lawful research supplier keeps every circumstance of its marketing consistent with research use, because under 21 CFR 201.128 that determines the legal category of what it sells [5]. That means RUO labeling on every unit, product descriptions confined to chemistry, sequence, purity and published literature, and no statements about effects or administration in humans.

Two further practices follow. A batch-specific certificate of analysis reporting HPLC purity and mass-spectrometry identity documents what the material is, the only representation a research supplier can properly make (see certificates of analysis and third-party testing). And the supplier does not describe accessories in a way that supplies the means of human administration [14]. A checklist appears in how to evaluate a research peptide supplier.

Muttenthaler and colleagues counted more than 80 peptide drugs that reached the market through approval pathways [19]. Each became lawful for human use by passing review; a research peptide has not, which is why a lawful supplier's silence on human use is the substance of its legal position.

Summary

Research peptides are lawful to manufacture, sell and buy in the United States when labeled and marketed solely for laboratory research; they become unapproved new drugs, and their sale a prohibited act under 21 U.S.C. 331 and 355, when marketed for human use. Peptides are not controlled substances as a class under 21 U.S.C. 812; anabolic steroids (non-peptide, Schedule III) and human growth hormone (21 U.S.C. 333(e)) are the verified exceptions.

The FDA has placed several peptides in category 2 of its compounding interim policies, scheduled others for advisory-committee review in July 2026, and issued warning letters in December 2024 and August 2026 rejecting RUO labels contradicted by website claims. WADA's 2026 list separately prohibits section S2 peptides for athletes at all times. This article is general legal information, not legal advice.

References

1. 21 U.S.C. 812. Schedules of controlled substances. Legal Information Institute, Cornell Law School
2. 21 U.S.C. 802(41). Definitions: "anabolic steroid." Legal Information Institute, Cornell Law School
3. 21 U.S.C. 333(e). Penalties: prohibited distribution of human growth hormone. Legal Information Institute, Cornell Law School
4. 21 U.S.C. 321(g)(1). Federal Food, Drug, and Cosmetic Act, definition of "drug." Legal Information Institute, Cornell Law School
5. 21 CFR 201.128. Meaning of "intended uses." Legal Information Institute, Cornell Law School
6. 21 U.S.C. 355(a). New drugs: necessity of effective approval of application. Legal Information Institute, Cornell Law School
7. 21 U.S.C. 331. Prohibited acts. Legal Information Institute, Cornell Law School
8. 21 U.S.C. 353a. Pharmacy compounding (FDCA section 503A). Legal Information Institute, Cornell Law School
9. 21 U.S.C. 353b. Outsourcing facilities (FDCA section 503B). Legal Information Institute, Cornell Law School
10. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Page current as of May 14, 2026. FDA
11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Page current as of April 22, 2026. FDA
12. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA
13. U.S. Food and Drug Administration. Warning Letter, Summit Research Peptides, MARCS-CMS 695607, December 10, 2024. FDA
14. U.S. Food and Drug Administration. Warning Letter, Peptide Partners LLC, MARCS-CMS 735063, August 24, 2026. FDA
15. World Anti-Doping Agency. The 2026 Prohibited List: International Standard. Effective January 1, 2026. WADA
16. Görgens C, Guddat S, Thomas A, Thevis M. Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (< 2 kDa) - sample preparation, mass spectrometric detection, and data review. Drug Test Anal. 2018;10(11-12):1755-1760. DOI: 10.1002/dta.2503 (PMID: 30239151)
17. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. DOI: 10.1002/dta.1402 (PMID: 22962027)
18. U.S. Food and Drug Administration. Personal Importation. FDA
19. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. DOI: 10.1038/s41573-020-00135-8 (PMID: 33536635)
20. U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff. November 2013. FDA guidance